前收市價 | 2.0500 |
開市 | 2.0000 |
買盤 | 0.0000 |
賣出價 | 2.5000 |
拍板 | 5.00 |
到期日 | 2024-05-17 |
今日波幅 | 2.0000 - 2.0500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 40 |
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 0% and 47.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.